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Abstract
Background: Alzheimer’s disease is the most common dementia in the elderly, and the potential of peripheral
biochemical markers as complementary tools in the neuropsychiatric evaluation of these patients has claimed
further attention.
Methods: We evaluated serum levels of S100B and neuron-specific enolase (NSE) in 54 mild, moderate and severe
Alzheimer’s disease (AD) patients and in 66 community-dwelling elderly. AD patients met the probable NINCDS-
ADRDA criteria. Severity of dementia was ascertained by the Clinical Dementia Rating (CDR) scale, cognitive
function by the Mini Mental State Examination (MMSE), and neuroimage findings with magnetic resonance
imaging. Serum was obtained from all individuals and frozen at -70°C until analysis.
Results: By comparing both groups, serum S100B levels were lower in AD group, while serum NSE levels were the
same both groups. In AD patients, S100B levels were positively correlated with CDR scores (rho = 0.269; p = 0.049)
and negatively correlated with MMSE scores (rho = -0.33; P = 0.048). NSE levels decreased in AD patients with
higher levels of brain atrophy.
Conclusions: The findings suggest that serum levels of S100B may be a marker for brain functional condition and
serum NSE levels may be a marker for morphological status in AD.
Background
Alzheimer’s disease (AD) is a progressive brain disorder
that results in memory impairment, personality altera-
tions, global cognitive dysfunction, and functional
impairments [1]. It is the most common dementia in
the elderly, accounting for 60-80% of cases, and it is
estimated to affect more than 4 million of USA citizens
[2]. The lifespan of individuals diagnosed with AD is
reduced by about 50% as compared with those of similar
age without disease, and the survival expectancy is nega-
tively associated with the severity of the disease at the
time of diagnosis [3]. Furthermore, there is no definitive
ante-mortem diagnostic test for AD, and when the clini-
cal diagnosis is made, is difficult to access and following
the course of neural cells loss [4].
The inherent hurdles of studying brain tissues in
human populations, especially in vivo,a r et h e
permanent stimulus for finding peripheral markers of
central nervous system (CNS) alterations. In this con-
text, a number of proteins have been proposed as per-
ipheral biochemical markers of neuronal damage and
glial injury/activation, which peripheral assessment may
represent a relevant step forward in the diagnostic and
monitoring of CNS diseases [5-9]. For this reason, the
clinical usefulness of peripheral biochemical markers as
complementary tool in the neuropsychiatric evaluation
has claimed further attention.
S100B and neuron specific enolase (NSE) are brain
derived proteins extensively studied as peripheral bio-
chemical markers for brain injury [8-11]. S100B is a cal-
cium binding protein physiologically produced and
released predominantly by astrocytes, whereas NSE is a
cytoplasmatic glycolytic pathway enzyme, being the gg
isoform mainly neuronal [12,13]. Since their levels may
increase in CSF and/or blood in several brain patholo-
gies, both proteins are considered to be markers of
astrocytic damage/reaction (S100B) and neuronal
damage (NSE) [14-16]. Considering the prominent
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have also attempted to clinically evaluate the levels of
these proteins, resulting in contradictory findings
[17-21], but alternatively, experimental and human stu-
dies have strengthened the belief that S100B is impli-
cated in the mechanisms underlying neurodegeneration
in AD [22-24]. Accordingly, it was reported an associa-
tion between the deposition of cerebral amyloid beta
protein and the presence of activated astrocytes over
expressing S100B.
Furthermore, life-long over expression of S100B in
Down syndrome patients and transgenic mice cause
neuronal and glial morphological alterations similar to
those found in AD patients, as well as behavioral deficits
in animals [17-19]. These conjectures have been the
rational for studying CSF/serum S100B and NSE levels
in AD as markers of neurodegeneration and severity of
the disease. Also, it is important to take into account
that, due to the insufficiency of professional, methodolo-
gical and background conditions, the diagnosis of AD in
non specialized centers may not be accurately per-
formed, which encourage identifying potential peripheral
biomarkers for AD, aiming an easier, accurate and wide-
spread diagnosis [4].
The major aim of our study was to evaluate serum
S100B and NSE levels (more readily assessed than CSF)
in AD patients and control elderly individuals without
pathological cognitive impairment. In addition, we
searched for correlations among their levels and the
severity of dementia, cognitive status and brain morpho-
logical changes accessed by MRI.
Methods
Participants and study design
A cross-sectional study with AD patients and control
community-dwelling elderly was carried out. Thirty six
AD patients met the probable NINCDS ADRDA criteria
[25] and were recruited from the Neurogeriatric outpati-
ent clinic of Hospital de Clínicas de Porto Alegre
(HCPA), Porto Alegre, RS, Brazil. Severity of dementia
was assigned with the Clinical Dementia Rating (CDR)
scale and the cognitive status was assessed by Mini
Mental State Examination (MMSE) [26-28]. The CDR is
a scale in which CDR = 0 denotes no cognitive impair-
ment, and the remaining points indicate various stages
of dementia: CDR = 1 - mild dementia, CDR = 2 - mod-
erate dementia, and CDR = 3 - severe dementia. Exclu-
sion criterion for patients was the presence of any other
neurological or psychiatric condition (except if asso-
ciated with AD), or diseases that could lead to confusion
in the diagnosis of AD.
A control group composed of 66 community-dwelling
elderly individuals was recruited from the catchment’s
a r e ao ft h es a m eh o s p i t a l .T h ei n c l u s i o nc r i t e r i aw e r e
age higher than 60 years and a CDR = 0. Controls were
excluded if they presented chronic renal disease, history
of significant head injury or stroke; other psychiatric
conditions such as major affective disorder or evidence
of current depression; uncorrectable vision or hearing
loss or other conditions such as substance abuse or use
of medications that could impair cognitive function.
AD patients were evaluated with brain magnetic reso-
nance imaging. Patients were additionally submitted to a
complete medical and laboratory evaluation. Educational
attainment was checked for all participants.
B l o o ds a m p l e s( 3m l )f o rS 1 0 0 Ba n dN S El e v e l sm e a -
surement were collected by venipuncture with a tube
(vacuum system) without anticoagulants by a trained
professional. Serum (was obtained by centrifugation at
5,000 × g for 5 min and, soon thereafter, it was frozen
at -70°C until analysis.
Brain MRI
Neuroimaging data were acquired with MRI equipments
of 1.5 T (Siemens Magneton Vision Plus or Siemens
Symphony, Siemens Medical Systems, Erlang, Germany)
with the axial SE and TSE pulse sequences, in T2, (TR:
7,100; TE: 115; slice width: 5 mm; FOV: 230; matrix:
345 × 512), FLAIR (TR: 9,000; TE: 110; slice width: 5
mm; FOV: 230; matrix: 154 × 256) and IR (TR: 1,450,
TE: 115, slice width: 3 mm, FOV: 200; matrix: 160 ×
256). Sagital SE images were also acquired in T1 (TR:
580; TE: 14; slice width: 5 mm; FOV: 260; matrix: 156 ×
256). The average duration of the exam was 30 minutes.
Degree of brain atrophy was measured according to
the method of Meese et al. 1980 [29]. Two transversal
lines were established in the axial plane of the brain, on
TSE pulse sequence, in T2. The first estimated the
latero-lateral diameter of the lateral ventricles (D1), and
the second, between the parietal bones. The brain atro-
phy index (BAI) was calculated by the equation BAI =
10 - (D2/D1).
Three degrees of brain atrophy were also established:
mild (level 1), moderate (level 2), and severe (level 3),
based on the 25, 50 and 75 percentile values of the
groups combined.
Serum S100B and NSE analyses
A quantitative monoclonal two-site immunoluminometric
assay LIA-mat Sangtec 100 (BYK-Sangtec, Germany), was
used for measuring S100B levels in 100 (L of samples. The
immunoluminometric assay is composed of three mono-
clonal antibodies specific to subunit b of S100 and a tracer
antibody, which is bound to isoluminol. Oxidation of iso-
luminol is started by injection of an alkaline peroxide solu-
tion and catalyst solution. The immunological reaction is
detected by light reaction [30]. The determinations were
carried out in two different experiments. The S100B
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for duplicates across the entire concentration range for the
calibrators and samples were < 5%. The detection limit of
the assay is 0.02 (μg/L, as provided by the supplier of the
LIA-mat Sangtec100 assay. Internal controls provided by
manufacturer was used to determine inter- assay variation,
which was also <5%. S100B levels are expressed as mean ±
standard deviation.
NSE level was evaluated in serum samples by an elec-
trochemiluminescence assay kit (ECLIA, Roche Diagnos-
tics, USA). This is a quantitative method that uses a
monoclonal antibody specific for NSE and labeled with
a ruthenium complex, which produces light emission
when excited [6]. Reactions and quantification were per-
formed in duplicate by a fully automatized equipment
Elecsys-2010 (Roche Diagnostics Corporation®). Internal
software and controls provided by the manufacturer
allow controlling the quality of assay. The NSE calibra-
tion curve was linear up to 370 (μg/L), and the CVs for
duplicates across the entire concentration range for the
calibrators, controls and samples were < 5%. The detec-
tion limit was 0.015 μg/L. Serum NSE level is expressed
as μg/L (mean ± S.D.).
Ethical aspects
The study was conducted in accordance with the Declara-
tion of Helsinki, and was approved by the Ethics Commit-
tee for Medical Research of the university hospital where
it was developed. Informed consent was obtained from the
subjects, their nearest relatives, or both.
Statistical analysis
Descriptive statistics are presented with mean ± stan-
dard deviation for parametric variables, and absolute
and percentage frequency for categories. Comparison of
S100B and NSE serum levels between groups was made
using one-way ANOVA with Tukey test, and Student’st
test for independent samples. Correlation between
S100B and MMSE was performed with Spearman’s coef-
ficient. Chi-square test with Yates or Fisher exact cor-
rection was used for the analysis of association of CDR
and MRI findings categories. Comparison ANOVA fol-
l o w e db yT u k e yt e s ta n dS t u d e n ttt e s tw e r eu s e dt o
analyze differences between serum levels of S100B (AD
and controls) and CDR groups. A p value < 0.05 was
considered statistically significant. Statistical analyses
were carried out with the SPSS 16.0 for Windows.
Results
Comparisons between AD and Control group
The demographic, clinical and biochemical characteris-
tics of AD patients and control elderly group are
depicted in Table 1. The MMSE and CDR scales were
altered in AD patients compared to control group.
There was a statistically significant difference in serum
S100B levels between AD and control group (0.08 ±
0.06 vs. 0.21 ± 0.36, μg/L, respectively; p = 0.008), while
the serum NSE levels were similar in both groups (9.28
± 3.86 vs. 9.54 ± 5.28, μg/L, respectively; p = 0.832).
Serum S100B and NSE levels did not vary with age
(data not shown).
Serum S100B and NSE levels in AD patients
A positive significant correlation among CDR scores and
S100B levels was observed among AD patients (rho =
0.269; p = 0.049, data not shown). Additionally, among
AD patients, there was a statistically significant differ-
ence in serum S100B levels between mild and severe
CDR scores (0.050 ± 0.013 vs. 0.091 ± 0.022, respec-
t i v e l y ;p=0 . 0 2 2 )( F i g u r e1 ) .N od i f f e r e n c e si ns e r u m
NSE level were observed among CDR categories of AD
patients (data not shown).
There was a significant negative correlation between
serum S100B levels and cognitive performance -
expressed as a positive correlation between S100B levels
and MMSE score (Spearman correlation rho = - 0.35; p
= 0.01; Figure 2). A negative correlation between serum
NSE levels and MMSE was also observed (Spearman
correlation rho = - 0.48; p = 0.017, data not shown).
MRI and S100 and NSE serum levels in AD patients
Table 2 shows the correlation among serum NSE and
S100B levels with the degree of brain atrophy accessed
by MRI in AD patients. NSE levels significantly
decreased with the brain atrophy severity. Serum S100B
levels were not affected by brain atrophy. Despite litera-
ture suggest the opposite [31]; there was no correlation
among severity of dementia (evaluated by CDR scale)
and the MRI findings (Table 3).
Table 1 Demographic, clinical and biochemical data of
subjects.
Control group
(N = 66)
AD patients
(N = 54)
P value
Age (years) (mean ± SD) 76.56 ± 5.46 77.13 ± 7.57 0.773
Gender
Male (%) 20 (30%) 18 (33%) 0.681
Female (%) 46 (70%) 36 (67%)
Education (in years) 8.48 ± 5.24 5.23 ± 4.38 0.01
MMSE (mean ± SD) 27.09 ± 2.99 10.98 ± 6.44 0.001
CDR (%)
0 66 (100%) - 0.001
1 (mild) - 12 (22%)
2 (moderate) - 22 (41%)
3 (severe) - 20 (37%)
S100B (μg/l) (mean ± SD) 0.21 ± 0.36 0.08 ± 0.06 0.008
NSE (μg/l) (mean ± SD) 9.54 ± 5.28 9.28 ± 3.86 0.832
MMSE: Mini Mental State Examination. CDR: Clinical Dementia Rating
Chaves et al. Journal of Neuroinflammation 2010, 7:6
http://www.jneuroinflammation.com/content/7/1/6
Page 3 of 7Discussion
The main goal of this work was to investigate the course
of brain neurodegenerative processes in AD patients
through biochemical brain markers, neuropsychological
and neuroimaging evaluations. Our main findings were:
i) although serum NSE levels were not different between
AD patients and control elderly individuals, serum of
S100B levels were significantly lower in DA patients; ii)
there were a positive correlation between S100B levels
and AD severity (evaluated by CDR and MMSE) as well
as a negative correlation between NSE levels and the
severity of morphological brain alterations, evaluated by
MRI.
In the last years the possibility of evaluating brain
damage/activity through quantification of neuronal and
glial derived proteins (such as S100B and NSE) in per-
ipheral samples has gained appropriate attention in clin-
ical and experimental settings [5,14,20,32]. However,
S100B and NSE proteins are also expressed in other non
neural cell types under physiological and pathological
conditions. Thus, the brain specificity of these proteins
has been questionable by some works, including from
our laboratory [33], when assessing serum samples.
Moreover, recent epidemiological and clinico-pathologic
data suggest overlaps between AD and cerebrovascular
lesions that may magnify the effect of mild AD pathol-
ogy and promote progression of cognitive decline or
even may precede neuronal damage and dementia [34].
So, we cannot rule out that vascular lesions also could
account for increase S100B levels.
Despite the controversies on their brain specificity,
S100B and NSE have been investigated in different brain
diseases as peripheral markers of therapeutic interven-
tions, as well as of neurological and neuropsychological
outcome [14,16,22-24]. Additionally, a recent work sug-
gests that blood-brain barrier permeability may also be
damaged even at an early stage of AD indicating differ-
ent blood-brain-CSF compartmental kinetics [35]. Thus,
the leakage of proteins from brain to blood could be
facilitated.
Figure 1 Serum S100B level (mean ± SD) according to severity
of dementia in AD (CDR scale; 1 mild, 2 moderate; 3 severe) -
One-way ANOVA (F = 3.685).
Figure 2 Correlation between S100B serum levels and Mini
Mental State Examination (MMSE) score: AD patients -
Spearman rho = - 0.35; P = 0.01.
Table 2 Serum S100B and NSE levels (mean ± SD)
according to brain MRI findings in AD patients.
Degree of brain atrophy
Percentil 25
(N = 16)
Percentil 50
(N = 26)
Percentil 75
(N = 12)
S100B 0.09 ± 0.05 0.07 ± 0.06 0.07 ± 0.06
NSE 14.52 ± 4.08
a,b 7.98 ± 1.52
a,c 6.64 ± 1.17
b,c
a ≠ a: p < 0.001
b ≠ b: p = 0.001
c ≠ c: p = 0.077
Table 3 Distribution of dementia severity (CDR
categories) according to brain MRI findings in AD
patients.
CDR Degree of brain atrophy
Percentil 25
(N = 16)
Percentil 50
(N = 26)
Percentil 75
(N = 12)
Mild (N = 12) 3 (19%) 7 (27%) 2 (17%)
Moderate (N = 22) 7 (44%) 8 (31%) 7 (58%)
Severe (N = 20) 6 (37.5%) 11 (42%) 3 (25%)
Chi-square Fisher Exact = 2.67; p = 0.632
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regarding CSF levels of S100B in AD, which from the per-
spective of cerebral protein release provides more sensitiv-
ity and specificity than serum samples, however, the
availability of CSF samples is somewhat limited for routine
clinical use [20,21,36]. These previous studies showed dis-
crepant results with respect to the differences in S100B
levels between AD and control groups and also to clinical
associations. While some studies have reported increased
CSF levels of S100B in AD patients compared to controls
[21,36], others did not find any difference [20]. There are
also reports suggesting a positive correlation between CSF
S100B levels and MMSE, and a negative correlation with
severity of dementia by CDR scale [20] while in others
CSF S100B levels did not correlate with impaired cognitive
status evaluated by MMSE [21,36].
In contrast to these cited works, here we demon-
strated AD patients a positive correlation between
serum S100B levels and brain function (evaluated by
MMSE and CDR). Ethnic differences, education, prior
l i f es t y l ea n dt h ep r e d o m i n a n c eo ff e m a l ei no u rs t u d y ,
compared to others, could account for the differences
observed among the previous published results. Consid-
ering that in our work MMSE and CDR scales identified
patients with impaired cerebral functionality affected by
AD and that the S100B levels were higher in more
severely affected patients, we preliminarily suggest that
serum S100B levels could help to distinguish severity or
to follow up the progression of dementia in AD disease,
even though the diagnosis is based on clinical investiga-
tions. This result may reflect the participation of this
protein in the pathogenesis of AD. Indeed, glial cells
particularly microglia and astrocytes are able to modu-
late cerebral plasticity and to protect brain from insults
[13]; thus, in this context the increase in S100B could
indicate astrocytic reaction to neuronal injury (reactive
astrogliosis) in AD patients. Once activated, these cells
increase the expression of substances that can partici-
pate in the excitotoxicity and inflammatory processes
that occur during the evolution of AD [37].
Further, dysfunction of glial cells may promote neu-
rodegeneration and, eventually, the retraction of neu-
ronal synapses, which leads to cognitive deficits [38].
However, our major concern is regarding the decreas-
ing levels of S100B in total AD group compared to
controls. This finding was confirmed by an additional
experiment with a new set of patients. Interestingly,
the severity of CDR score was associated with eleva-
tions in serum S100B levels, contrasting to our pre-
vious findings with schizophrenic patients [39], when
t h el e v e l sw e r em o r ee l e v a t e di nt h ee a r l yo n s e to fd i s -
ease. In this context, increased astrocytic expression of
S100B could be involved in the progression of brain
neuropathological changes and behavioral deficits
observed in patients and animal models [20,13,40-42].
W h i l ei nt h i ss t u d yS 1 0 0 Bl e v e l si nA Dp a t i e n t sd i d
not correlate with brain morphological changes evalu-
ated by MRI, lower serum levels of NSE were related
to higher degree of atrophy and brain macroscopic
alterations. Furthermore, this loss was not associated
with dementia severity in AD patients. The lack of a
correlation with atrophy and cognition reported here is
somewhat curious as many recent reports of the litera-
ture suggest the opposite [31].
Levels of NSE have been shown to be elevated in
acute phase of several disorders of the CNS [43-47].
This data could preliminary suggest that AD patients,
prior the onset of symptoms, could have altered NSE
levels, which is now reflected by brain atrophy and ven-
tricle enlargement. However, the reports of CSF NSE
vary from decreased levels [17], no difference [19] to
increased levels [48]. Interestingly, Palumbo et al. 2008
[48] showed that CSF NSE lev e lh a st h es a m eb e h a v i o r
as the other accepted markers of AD, being correlated
with Abeta42 and total protein tau (h-tau).
Taking into consideration, the strong association of
the prognosis of AD patients with the severity of
dementia at the diagnosis [3], and the difficulty of evalu-
ating the degree of neural cells loss in AD [4], further
experimental and clinical studies regarding these serum
markers in AD disease should be encouraged.
Conclusions
In conclusion, we showed that in AD patients the serum
S100B levels increased with the severity of the disease
whereas decreased serum levels of NSE were associated
with increased brain morphological damage.
Acknowledgements
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES),
Fundação de Amparo à Pesquisa do Rio Grande do Sul (FAPERGS) and
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq),
IBN.Net/Finep, INCT for Excitotoxicity and Neuroprotection/CNPq.
Author details
1Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Rua Ramiro
Barcelos 2350, 90035-003 Porto Alegre, RS, Brazil.
2Programa de Pós-
graduação em Bioquímica, PPG-Bioq. Departamento de Bioquímica, ICBS,
UFRGS, Ramiro Barcelos 2600, anexo, 90035-003 Porto Alegre, RS, Brazil.
Authors’ contributions
MLC designed the study, was responsible for the statistical design of the
study, supervised the data collection, and wrote the manuscript. ALC was
responsible for carrying out the statistical analysis and helped with
reviewing the manuscript. EDF supervised the data collection, was
responsible for carrying out the statistical analysis and wrote the manuscript.
IP, RK, OD and GSM collected the data and assisted with writing the
manuscript. DOS and LVP designed the study, made the biochemical
measurements and reviewed the manuscript. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Chaves et al. Journal of Neuroinflammation 2010, 7:6
http://www.jneuroinflammation.com/content/7/1/6
Page 5 of 7Received: 4 May 2009
Accepted: 27 January 2010 Published: 27 January 2010
References
1. Juva K, Sulkava R, Erkinjuntti T, Ylikoski R, Valvanne J, Tilvis R: Staging the
severity of dementia: comparison of clinical (CDR, DSM-III-R), functional
(ADL, IADL) and cognitive (MMSE) scales. Acta Neurol Scand 1994,
90:293-298.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer disease
in the US population: prevalence estimates using the 2000 census. Arch
Neurol 2003, 60:1119-1122.
3. Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L,
Kukull WA: Survival after initial diagnosis of Alzheimer disease. Ann Intern
Med 2004, 140:501-509.
4. Growdon JH: Biomarkers of Alzheimer disease. Arch Neurol 1999,
56:281-283.
5. Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F,
Souza DO, Portela LV, Gentil V: Decreased plasma brain derived
neurotrophic factor levels in unmedicated bipolar patients during manic
episode. Biol Psychiatry 2007, 61:142-144.
6. Oses JP, Leke R, Portela LV, Lara DR, Schmidt AP, Casali EA, Wofchuk S,
Souza DO, Sarkis JJ: Biochemical brain markers and purinergic
parameters in rat CSF after seizure induced by pentylenetetrazol. Brain
Res Bull 2004, 64:237-242.
7. Herrmann M, Jost S, Kutz S, Ebert AD, Kratz T, Wunderlich MT, Synowitz H:
Temporal profile of release of neurobiochemical markers of brain
damage after traumatic brain injury is associated with intracranial
pathology as demonstrated in cranial computerized tomography. J
Neurotrauma 2000, 17:113-122.
8. Wunderlich MT, Wallesch CW, Goertler M: Release of glial fibrillary acidic
protein is related to the neurovascular status in acute ischemic stroke.
Eur J Neurol 2006, 13:1118-1123.
9. Schaf DV, Tort AB, Fricke D, Schestatsky P, Portela LV, Souza DO, Rieder CR:
S100B and NSE serum levels in patients with Parkinson’s disease.
Parkinsonism Relat Disord 2005, 11:39-43.
10. Herrmann M, Ebert AD, Galazky I, Wunderlich MT, Kunz WS, Huth C:
Neurobehavioral outcome prediction after cardiac surgery: role of
neurobiochemical markers of damage to neuronal and glial brain tissue.
Stroke 2000, 31:645-650.
11. Busnello JV, Leke R, Oses JP, Feier G, Bruch R, Quevedo J, Kapczinski F,
Souza DO, Portela LV: Acute and chronic electroconvulsive shock in rats:
effects on peripheral markers of neuronal injury and glial activity. Life Sci
2006, 78:3013-3017.
12. Kaiser E, Kuzmits R, Pregant P, Burghuber O, Worofka W: Clinical
biochemistry of neuron specific enolase. Clin Chim Acta 1989, 183:13-32.
13. Van Eldik LJ, Wainwright MS: The Janus face of glial-derived S100B:
beneficial and detrimental functions in the brain. Restor Neurol Neurosci
2003, 21:97-108.
14. Herrmann M, Ehrenreich H: Brain derived proteins as markers of acute
stroke: their relation to pathophysiology, outcome prediction and
neuroprotective drug monitoring. Restor Neurol Neurosci 2003, 21:177-190.
15. Steiner J, Bielau H, Bernstein HG, Bogerts B, Wunderlich MT: Increased
cerebrospinal fluid and serum levels of S100B in first-onset
schizophrenia are not related to a degenerative release of glial fibrillar
acidic protein, myelin basic protein and neurone-specific enolase from
glia or neurones. J Neurol Neurosurg Psychiatry 2006, 77:1284-1287.
16. Rothermundt M, Ohrmann P, Abel S, Siegmund A, Pedersen A, Ponath G,
Suslow T, Peters M, Kaestner F, Heindel W, Arolt V, Pfleiderer B: Glial cell
activation in a subgroup of patients with schizophrenia indicated by
increased S100B serum concentrations and elevated myo-inositol. Prog
Neuropsychopharmacol Biol Psychiatry 2007, 31:361-364.
17. Cutler NR, Kay AD, Marangos PJ, Burg C: Cerebrospinal fluid neuron-
specific enolase is reduced in Alzheimer’s disease. Arch Neurol 1986,
43:153-154.
18. Blennow K, Wallin A, Ekman R: Neuron specific enolase in cerebrospinal
fluid: a biochemical marker for neuronal degeneration in dementia
disorders?. J Neural Transm Park Dis Dement Sect 1994, 8:183-191.
19. Parnetti L, Palumbo B, Cardinali L, Loreti F, Chionne F, Cecchetti R, Senin U:
Cerebrospinal fluid neuron-specific enolase in Alzheimer’s disease and
vascular dementia. Neurosci Lett 1995, 183:43-45.
20. Whitaker-Azmitia PM, Wingate M, Borella A, Gerlai R, Roder J, Azmitia EC:
Transgenic mice overexpressing the neurotrophic factor S-100 beta
show neuronal cytoskeletal and behavioral signs of altered aging
processes: implications for Alzheimer’s disease and Down’s syndrome.
Brain Res 1997, 776:51-60.
21. Griffin WS, Sheng JG, McKenzie JE, Royston MC, Gentleman SM,
Brumback RA, Cork LC, Del Bigio MR, Roberts GW, Mrak RE: Life-long
overexpression of S100beta in Down’s syndrome: implications for
Alzheimer pathogenesis. Neurobiol Aging 1998, 19:401-405.
22. Mrak RE, Griffin WS: The role of activated astrocytes and of the
neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease.
Neurobiol Aging 2001, 22:915-922.
23. Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ: Cerebrospinal
fluid S100B is elevated in the earlier stages of Alzheimer’s disease.
Neurochem Int 2001, 39:409-413.
24. Petzold A, Jenkins R, Watt HC, Green AJ, Thompson EJ, Keir G, Fox NC,
Rossor MN: Cerebrospinal fluid S100B correlates with brain atrophy in
Alzheimer’s disease. Neurosci Lett 2003, 336:167-170.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM:
Clinical diagnosis of Alzheimer’s disease: report of NINCDS-ADRDA Work
Group under the auspices of Department of Health and Human Services
Task Force on Alzheimer’s Disease. Neurology 1984, 34:939-944.
26. Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”. A practical
method for grading the cognitive state of patients for the clinician. J
Psychiatr Res 1975, 12:189-198.
27. Chaves ML, Izquierdo I: Differential diagnosis between dementia and
depression: a study of efficiency increment. Acta Neurol Scand 1992,
85:378-382.
28. Chaves ML, Camozzato AL, Godinho C, Kochhann R, Schuh A, de
Almeida VL, Kaye J: Validity of the Clinical Dementia Rating Scale for The
Detection and Staging of Dementia in Brazilian Patients. Alzheimer Dis
Assoc Disord 2007, 21:210-217.
29. Meese W, Kluge W, Grumme T, Hopfenmuller W: CT evaluation of the CSF
spaces of healthy persons. Neuroradiology 1980, 19:131-136.
30. Portela LV, Tort AB, Schaf DV, Ribeiro L, Nora DB, Walz R, Rotta LN, Silva CT,
Busnello JV, Kapczinski F, Gonçalves CA, Souza DO: The serum S100B
concentration is age dependent. Clin Chem 2002, 48:950-952.
31. Davatzikos C, Xu F, An Y, Fan Y, Resnick SM: Longitudinal progression of
Alzheimer’s-like patterns of atrophy in normal older adults: the SPARE-
AD index. Brain 2009, 132:2026-2035.
32. Busnello JV, Oses JP, da Silva RS, Feier G, Barichello T, Quevedo J,
Böhmer AE, Kapczinski F, Souza DO, Sarkis JJ, Portela LV: Peripheral
nucleotide hydrolysis in rats submitted to a model of electroconvulsive.
Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1829-1833.
33. Mazzini GS, Souza DO, Portela LV: The ischemic heart as an extracerebral
source for S100B. Resuscitation 2009, 80:144.
34. Jellinger KA: Alzheimer disease and cerebrovascular pathology: an
update. J Neural Transm 2002, 109:813-836.
35. Starr JM, Farrall AJ, Armitage P, McGurn B, Wardlaw J: Blood-brain barrier
permeability in Alzheimer’s disease: a case-control MRI study. Psychiatry
Res 2009, 171:232-241.
36. Green AJ, Harvey RJ, Thompson EJ, Rossor MN: Increased S100beta in the
cerebrospinal fluid of patients with frontotemporal dementia. Neurosci
Lett 1997, 235:5-8.
37. Farfara D, Lifshitz V, Frenkel D: Neuroprotective and neurotoxic properties
of glial cells in the pathogenesis of Alzheimer’s disease. J Cell Mol Med
2008, 12:762-780.
38. Schwab C, McGeer PL: Inflammatory aspects of Alzheimer disease and
other neurodegenerative disorders. J Alzheimers Dis 2008, 13:359-369.
39. Lara DR, Gama CS, Belmonte-de-Abreu P, Portela LV, Gonçalves CA,
Fonseca M, Hauck S, Souza DO: Increased serum S100B protein in
schizophrenia: a study in medication-free patients. J Psych Res 2001,
35:11-14.
40. Marshak DR, Pesce SA, Stanley LC, Griffin WS: Increased S100 beta
neurotrophic activity in Alzheimer’s disease temporal lobe. Neurobiol
Aging 1992, 13:1-7.
41. Sheng JG, Mrak RE, Griffin WS: S100 beta protein expression in Alzheimer
disease: potential role in the pathogenesis of neuritic plaques. J Neurosci
Res 1994, 39:398-404.
42. Mrak RE, Griffin WS: Trisomy 21 and the brain. J Neuropathol Exp Neurol
2004, 63:679-685.
Chaves et al. Journal of Neuroinflammation 2010, 7:6
http://www.jneuroinflammation.com/content/7/1/6
Page 6 of 743. Hay E, Royds JA, Davies-Jones GA, Lewtas NA, Timperley WR, Taylor CB:
Cerebrospinal fluid enolase in stroke. J Neurol Neurosurg Psychiatry 1984,
47:724-729.
44. Persson L, Hardemark HG, Gustafsson J, Rundstrom G, Mendel-Hartvig I,
Esscher T, Pahlman S: S-100 protein and neuron-specific enolase in
cerebrospinal fluid and serum: markers of cell damage in human central
nervous system. Stroke 1987, 18:911-918.
45. Roine RO, Somer H, Kaste M, Viinikka L, Karonen SL: Neurological outcome
after out-of-hospital cardiac arrest. Prediction by cerebrospinal fluid
enzyme analysis. Arch Neurology 1989, 46:753-756.
46. Studahl M, Rosengren L, Gunther G, Hagberg L: Difference in pathogenesis
between herpes simplex virus type 1 encephalitis and tick-borne
encephalitis demonstrated by means of cerebrospinal fluid markers of
glial and neuronal destruction. J Neurol 2000, 247:636-642.
47. Correale J, Rabinowicz AL, Heck CN, Smith TD, Loskota WJ, DeGiorgio CM:
Status epilepticus increases CSF levels of neuron-specific enolase and
alters the blood-brain barrier. Neurology 1998, 50:1388-1391.
48. Palumbo B, Siepi D, Sabalich I, Tranfaglia C, Parnetti L: Cerebrospinal fluid
neuron-specific enolase: a further marker of Alzheimer’s disease?. Funct
Neurol 2008, 23:93-96.
doi:10.1186/1742-2094-7-6
Cite this article as: Chaves et al.: Serum levels of S100B and NSE
proteins in Alzheimer’s disease patients. Journal of Neuroinflammation
2010 7:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Chaves et al. Journal of Neuroinflammation 2010, 7:6
http://www.jneuroinflammation.com/content/7/1/6
Page 7 of 7